Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Healthineers scores big in the third quarter
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
Covid-19 takes its toll on medtechs’ efficiency
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
